Late effects in humans after intravenous treatment with 224Ra
1473 ankylosing spondylitis patients, who have been treated for their disease with repeated intravenous injections of Radium-224, are compared with a control group of 1338 ankylosing spondylitis patients not treated with Radium-224 or X-rays, in order to provide information on causes of death and lesions possibly related to the basic disease itself or to chemotherapy. So far, 495 patients in the exposure group and 602 patients in the control group have died. Until now, after a mean follow-up time of 17 years, three cases of malignant tumours in the skeleton have been observed in the exposure group (0.4 - 0.7 expected naturally, p = 0.034) vs. one case in the control group. The incidence of chronic myeloid leukaemias (3 in the exposure group vs. no case in the control group) is discussed, in comparison to other groups of patients treated with higher as well as with lower doses and dose rates of Radium-224.
Bibliographic Reference: Paper presented: EULEP Task Group Meeting, Oxford (GB), Nov. 7-9, 1988
Availability: Text not available
Record Number: 198910862 / Last updated on: 1994-12-01
Original language: en
Available languages: en